Startup TrX1 develops cell therapies that function like a particular type of regulatory T cell, or Treg, whose role includes dampening inflammation and inducing long-term tolerance. Based on research from Stanford, TrX1’s lead program is a potential therapy for preventing graft-versus-host disease.
AstraZeneca is paying $85 million to kick off an alliance with Quell Therapeutics focused on developing new cell therapies for autoimmune diseases. Type 1 diabetes and inflammatory bowel disease are the focus of the research collaboration.
Explore the top mobile IV therapy companies boosting immune health on demand, with standout services, expert care and innovative delivery across the U.S.
Regeneron is paying Sonoma Biotherapeutics $75 million to begin a partnership focused on developing cell therapies based on regulatory T cells, or Tregs. Each company brings technological capabilities to the alliance, which is initially focused on ulcerative colitis and Crohn’s disease.
Quell Therapeutics' $156 million Series B round comes as it prepares to advance to a clinical trial testing its lead regulatory T cell therapy candidate as way to prevent organ rejection in liver transplant patients. The progress is part of a growing field of Treg cell therapy developers that is becoming increasingly competitive.